Join to view full profile
450 Brookline AveBoston, MA 02215
Phone+1 617-632-3270
Fax+1 617-632-4410
Dr. Majzner is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 2016
New York Presbyterian Hospital (Columbia Campus)Residency, Pediatrics, 2009 - 2012
Harvard Medical SchoolClass of 2009
Certifications & Licensure
MA State Medical License 2023 - 2028
CA State Medical License 2016 - 2024
MD State Medical License 2014 - 2017
NY State Medical License 2010 - 2014
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- Anti-CAR Immunity Drives Acquired Therapeutic Resistance to GD2-CAR T Cell Therapy in Diffuse Midline Glioma.Yiyun Chen, Kevin Reynolds, Maximilian R A Koch, Camille F Petrakian, Zinaida Good
Medrxiv. 2026-07-09 - 12 citationsEngineering chimeric antigen receptor CD4 T cells for Alzheimer's disease.Pavle Boskovic, Rotem Shalita, Wenqing Gao, Hailey Vernon, Yu Lin Deng
Proceedings of the National Academy of Sciences of the United States of America. 2026-02-17 - 6 citationsEngineering T cells with a membrane-tethered version of SLP-76 overcomes antigen-low resistance to CAR T cell therapy.Maria Caterina Rotiroti, Aidan M Tousley, Hoyin Chu, Marco Herrera-Barrera, Antigoni Manousopoulou
Nature Cancer. 2025-12-01
Journal Articles
- Tumor Antigen Escape from CAR T-cell TherapyCrystal L Mackall, Robbie G Majzner, Clinical Cancer Research
Abstracts/Posters
- Identification of Dual Positive CD19+/CD3+ T Cells in an Apheresis Product Undergoing Chimeric Antigen Receptor (CAR) TransductionRobbie G. Majzner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)Robbie G. Majzner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- CAR T Cell Therapy for NeuroblastomaRobbie Majzner, MD, Frontiers in Neurology, Orlando, FL, 12/9/2019
Press Mentions
Experimental Treatment Borrowed from Blood Cancer Shows Promise for Pediatric Brain TumorsMarch 19th, 2025- Novel Treatment Shows Promise Against Rare Cancer in KidsApril 6th, 2023
- Promising Treatment for Rare Cancer in Children Gives Hope to ExpertsApril 6th, 2023
Grant Support
- Immunotherapeutic targeting of gangliosides in Ewing SarcomaDANA-FARBER CANCER INST2023–2028
- Immunotherapeutic targeting of gangliosides in Ewing SarcomaDANA-FARBER CANCER INST2023–2028
- Engineered T cell approaches for Alzheimer's diseaseWASHINGTON UNIVERSITY2025–2027
- NexTGen - DFCIDANA-FARBER CANCER INST2023–2027
- Hijacking the T cell machinery for logic-gated CAR T cell controlDANA-FARBER CANCER INST2021–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: